Across TCGA pan-cancer cohorts, DCDC2B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DCDC2B data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DCDC2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCDC2B expression acts as an unfavorable survival marker.

LUAD and LSCC are the cancer types where DCDC2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.825	0.965	.025	6	view →
LSCC	DFS	Median	II,III,IV	0.913	1.000	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: DCDC2B tumor-vs-normal RNA expression · all DCDC2B data types